Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ).

The biotech firm’s shares jumped soared 13% in premarket trading following the announcement.

Novavax (NASDAQ:NVAX ) disclosed last month that the trial had been paused after a participant who received the combination vaccine initially reported symptoms suggestive of motor neuropathy, which affects the nerves controlling muscle movement.

The company later submitted additional data to the FDA, clarifying that the participant’s symptoms were more accurately linked to amyotrophic lateral sclerosis (ALS), a neurological condition impacting nerve cells in the brain and spinal cord.

Novavax stated that assessments found no connection between the symptoms and its vaccine.

"We thank the FDA for their partnership and thorough review of the additional information provided as part of our response package," said Robert Walker, Chief Medical (TASE:PMCN ) Officer of Novavax.

"The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine. We plan to start our Phase 3 trial as soon as possible."

A clinical hold is an FDA directive that instructs a drug manufacturer to delay or halt a planned clinical study. The move triggered a sharp drop in Novavax shares last month.

Novavax then stated that it did not believe there was a confirmed link between its vaccine and the reported nerve damage in the patient.

Public health officials consider Novavax's protein-based COVID vaccine to be a valuable choice for individuals hesitant to receive the mRNA vaccines from Pfizer (NYSE:PFE ) and Moderna (NASDAQ:MRNA ).

Unlike mRNA technology, which prompts cells to produce proteins that stimulate an immune response to COVID, Novavax’s approach relies on protein-based technology—a well-established method used for years in vaccines against diseases like hepatitis B and shingles.

Source: Investing.com

Последние публикации
BYD says it sets negotiable price cut targets for suppliers
27.11.2024 - 07:00
Australia stocks higher at close of trade; S&P/ASX 200 up 0.57%
27.11.2024 - 07:00
OpenAI allows employees to sell $1.5 billion stock to SoftBank, CNBC reports
27.11.2024 - 07:00
OpenAI employees to sell $1.5 bln in shares to SoftBank- CNBC
27.11.2024 - 07:00
Asia stocks drift lower; Chinese shares defy Trump tariff threats
27.11.2024 - 06:00
China's BYD sets negotiable price reduction targets for suppliers
27.11.2024 - 06:00
FAA will not require immediate 737 MAX engine action after bird strikes
27.11.2024 - 06:00
Australia moves closer to ban social media for children
27.11.2024 - 06:00
Turkey scales down $23 billion F-16 jet deal with US, minister says
27.11.2024 - 06:00
Taiwan's Foxconn says global manufacturing footprint to shield it from Trump's tariffs
27.11.2024 - 05:00
Trump taps Kevin Hassett to head National Economic Council
27.11.2024 - 04:00
Hyundai Motor to buy back $716 million worth of shares
27.11.2024 - 04:00
Trump tariffs could hurt S&P 500 earnings by ‘few percentage points’- Citi
27.11.2024 - 04:00
Hyundai Motor: Morgan Stanley Overweight, sees resilience against US tariffs
27.11.2024 - 03:00
China courier group S.F. Holding's shares open flat in Hong Kong trading debut
27.11.2024 - 03:00

© Analytic DC. All Rights Reserved.

new
Анализ рынка Как повлият завтра отчет NFP на курс доллара США?